"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label Investing. Show all posts
Showing posts with label Investing. Show all posts

Tuesday, November 17, 2026

An Alternative to an Uncertain AI Trade - medicine and, in particular, Genetics

 


Investment Note: Gene editing in focus

Why I like BEAM, CRSP and NTLA 

The Next Medical Revolution — and an Alternative to an Uncertain AI Trade

November 16, 2026 | Investment horizon: 2027–2028

A potentially historic turning point in medicine

Over the past several years, much of the investment world's attention and capital has been concentrated on artificial intelligence, semiconductors, data centres and the enormous infrastructure required to support them.

While AI will undoubtedly remain an important technological revolution, I believe another transformation is unfolding that may ultimately prove just as significant to humanity: the ability to treat, correct and potentially cure serious diseases by editing human genes.

This is no longer simply theoretical science.

Three publicly traded biotechnology companies—Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA)—are approaching important milestones that could help move genetic medicine from specialized experimental treatments toward broader commercial adoption.

Two years ago I took positions in all three, with BEAM as my principal investment, CRSP as the more commercially established complement and NTLA as the higher-risk, potentially higher-reward opportunity. I exited those positions in favor of the Ai buildout trade.  I am now considering entering positions again.

1. Beam Therapeutics (BEAM): My first choice

Beam is developing base editing, a technology designed to make precise changes to individual DNA letters without requiring the conventional double-strand DNA cuts associated with earlier CRISPR approaches.

This potentially provides a more precise way of addressing the genetic causes of disease.

On November 10, 2026, Beam announced positive pivotal results for risto-cel, its investigational sickle-cell treatment. The trial met its primary efficacy and safety endpoints, and the company expects to submit its FDA application as early as year-end 2026.

Equally important is BEAM-302, which aims to correct the underlying genetic defect responsible for alpha-1 antitrypsin deficiency, a serious inherited condition affecting the lungs and liver. Early clinical evidence suggests the treatment is producing the intended biological effects.

Beam reported approximately US$1 billion in cash and marketable securities at September 30, 2026. Its projected funding runway extends into mid-2029, including a conditional financing draw.

Why I am interested: Beam combines a potentially revolutionary technology platform with increasingly convincing clinical evidence, several development programs and sufficient financial resources to pursue major milestones.

I also believe its proprietary technology could make it an attractive strategic acquisition candidate for a larger pharmaceutical company seeking to expand into genetic medicine.

2. CRISPR Therapeutics (CRSP): The commercial validation

CRISPR Therapeutics has already achieved something that many biotechnology companies spend decades pursuing: bringing a gene-editing medicine to market.

Its CASGEVY treatment, developed with Vertex Pharmaceuticals, is approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.

CASGEVY generated approximately US$99 million in product revenue during the third quarter of 2026, representing 30% sequential growth. More than 750 patients worldwide had initiated treatment.

CRSP is also developing CTX310, an investigational in-body gene-editing treatment targeting serious lipid disorders. If successful, its applications could extend beyond rare genetic diseases into much larger cardiovascular markets.

The company reported approximately US$2.28 billion in cash and marketable securities, although part of that balance reflects convertible-debt financing.

Why I am interested: CRSP provides tangible evidence that gene-editing medicine can become a commercial business. Its substantial financial resources, expanding pipeline and relationship with Vertex strengthen the long-term investment case.

A potential acquisition by Vertex or another pharmaceutical company is conceivable, although existing partnerships may reduce the need for a full takeover.

3. Intellia Therapeutics (NTLA): The potentially historic catalyst

Intellia may be approaching one of the most consequential regulatory milestones in genetic medicine.

Its investigational lonvo-z treatment is designed to provide a one-time therapy for hereditary angioedema, a serious disorder that causes recurrent swelling attacks.

In Phase 3 testing, the treatment reduced attacks by approximately 87% compared with placebo over six months.

The FDA has accepted Intellia's application, with a target decision date of March 10, 2027.

If approved, lonvo-z could become the world's first commercially approved treatment that uses CRISPR to edit genes directly inside the human body.

That distinction is enormously important. Rather than removing cells, modifying them in a laboratory and returning them to the patient, in-body gene editing offers the prospect of simpler treatment delivery for certain diseases.

Intellia also has a strategic relationship with Regeneron Pharmaceuticals.

Why I am interested: NTLA offers the possibility of a major regulatory and commercial breakthrough within months. Its comparatively smaller market capitalization could make successful commercialization particularly meaningful to shareholders.

However, the company has experienced safety concerns in a separate gene-editing program, and FDA approval is not assured. I would therefore treat NTLA as the smallest and most speculative of the three investments.

4. Why Big Pharma could become interested

Large pharmaceutical companies face a continuing challenge: important medicines eventually lose patent protection, exposing billions of dollars in annual revenue to generic and biosimilar competition.

Acquiring innovative biotechnology companies is one way to replenish their development pipelines and obtain technologies that could underpin future generations of treatments.

Gene editing is especially attractive because it offers the possibility of treating diseases at their genetic source rather than managing symptoms indefinitely.

I see three potential reasons for acquisition interest:

  • Proprietary technology: A successful gene-editing platform could generate numerous future medicines, making the technology itself strategically valuable.

  • Clinical and regulatory validation: As treatments demonstrate efficacy and obtain approvals, some of the uncertainty facing potential acquirers diminishes.

  • Access to new markets: Successful gene-editing therapies for cardiovascular, metabolic and other widespread diseases could create much larger commercial opportunities than today's initial rare-disease applications.

Beam's base-editing platform, CRSP's approved treatment and Intellia's in-body editing capabilities each represent different strategic opportunities.

Existing relationships involving Pfizer, Eli Lilly, Vertex and Regeneron illustrate the pharmaceutical industry's interest in these technologies.

I consider Beam the most interesting potential acquisition candidate, followed by Intellia and CRISPR Therapeutics. This is a judgment about strategic attractiveness, not evidence of current acquisition discussions.

Importantly, my investment thesis does not depend on a takeover. These businesses must ultimately create value through successful medicines, commercialization and sustainable economics.

5. Why consider these investments now, amid the Nvidia controversy?

The timing of this opportunity is particularly interesting.

Nvidia's co-founder Jensen Huang resigned in November following reports concerning his personal conduct and allegations involving a suspected foreign-intelligence connection.

The controversy has raised questions about corporate governance, leadership succession and Nvidia's future strategic direction. The intelligence-related allegations remain unproven, and Nvidia has stated that it has no reason to believe company secrets were compromised.

More broadly, investors are increasingly questioning the financial structure supporting the AI infrastructure boom.

Enormous capital commitments, complex financing arrangements, circular investment relationships and uncertainty about future returns on AI spending have created concern about whether the market has become excessively dependent on a relatively small number of technology companies.

I do not believe this necessarily means the AI revolution is ending.

However, a temporary correction in AI-related equities could encourage investors to reconsider where the next major technological and commercial opportunities will emerge.

Genetic medicine offers a compelling alternative.

Unlike an AI infrastructure investment, whose immediate financial prospects may depend on continued data-centre construction and semiconductor spending, biotechnology companies can experience substantial valuation changes following successful clinical trials, FDA approvals and commercial adoption.

Their catalysts are different.

This does not make biotechnology immune to market corrections. Smaller biotechnology stocks are often highly sensitive to interest rates, liquidity and investor risk appetite. A broad technology selloff could initially drag biotechnology shares lower as well.

Nevertheless, over a two-year horizon, I believe successful genetic-medicine companies could develop investment momentum based on their own medical and commercial achievements, rather than the trajectory of AI infrastructure spending.

6. My proposed investment approach

I favour taking positions gradually rather than attempting to predict the precise bottom in any of these stocks.

Within a dedicated speculative genetic-medicine allocation, my preferred weighting would be:

CompanyAllocationInvestment role
BEAM45%Primary technology and growth position
CRSP40%Commercial validation and broader pipeline
NTLA15%Higher-risk regulatory and takeover optionality

I would initially establish partial positions and retain capital to take advantage of market weakness or additional clinical evidence.

There are meaningful risks: disappointing trial results, regulatory setbacks, unexpected safety problems, expensive commercialization, dilution and prolonged operating losses. The three companies also share substantial exposure to the same emerging field, making this a concentrated investment rather than a diversified healthcare portfolio.

7. My investment conclusion

I believe we may be approaching an important inflection point in genetic medicine.

For decades, many inherited diseases could be managed but not fundamentally corrected. Today, companies such as Beam, CRISPR Therapeutics and Intellia are demonstrating that this limitation may increasingly be overcome.

The medical implications are extraordinary, and the commercial implications could be substantial.

At the same time, uncertainty surrounding Nvidia, the financing of the AI infrastructure boom and the concentration of market capital in a handful of technology companies makes it sensible to investigate other sources of long-term growth.

My interest in BEAM, CRSP and NTLA is therefore based on three converging opportunities:

  1. The transition of gene editing from experimental science toward commercial medicine.

  2. The possibility that major pharmaceutical companies will increasingly seek to acquire or partner with developers of proprietary genetic technologies.

  3. The opportunity to diversify growth capital into a potentially transformative industry whose fundamental catalysts differ from those driving the AI infrastructure trade.

I regard BEAM as my first choice, CRSP as my second and NTLA as a smaller, higher-risk third position.

The next 24 months could prove particularly important as regulatory decisions, clinical results and commercialization provide clearer evidence of which companies will become leaders in genetic medicine.

The opportunity is substantial, but success is not assured. I would pursue these investments with a multi-year horizon, disciplined position sizing and a willingness to reassess the thesis as clinical and financial evidence develops.

The central investment proposition is simple: while markets debate the next phase of artificial intelligence, a revolution in the treatment of human disease may already be entering its commercial era.

Investment research note — November 16, 2026. This reflects a speculative investment thesis, not guaranteed returns or confirmed takeover interest.

Research supporting the note

The principal clinical and financial information comes from the companies' November 2026 disclosures: Beam's pivotal clinical results, CRISPR Therapeutics' Q3 results and Intellia's Q3 results.

Beam Therapeutics+2

For the Nvidia discussion, Reuters reports Huang's resignation and the related governance concerns, while distinguishing allegations from established wrongdoing. Reuters also identifies investor scrutiny of AI financing arrangements and Nvidia's leadership transition

Ed Note:

I would not disregard the possible takeover value of these three as their cutting edge technology develops and commercializes. Big Pharma is always on the lookout for such tasty morsels!

Tuesday, September 1, 2026

Do you have dry powder for the "Great Ai rotation"? 10 Stocks we like for the next 3 to 12 months!


                  Despite reports to the contrary, the Ai buildout continues to grow!

The Great AI Rotation Fall 2026

10 Stocks Positioned for the Next Phase of AI Infrastructure

September 1, 2026 — A RetireFund Working Investment Report

The next leg of AI spending is increasingly moving beyond GPUs and into the bottlenecks surrounding them—memory, optical connectivity, Ethernet/copper networking, custom silicon, power delivery, cooling and physical data-center systems.

That thesis remains intact despite today's weak tape. On September 1, the S&P 500 fell 0.71% and the Nasdaq 1.03% as long-term yields rose and oil prices jumped. That macro backdrop argues for staged entries rather than chasing rebounds, particularly because several of the best AI-infrastructure names have already undergone significant corrections.

My conclusion after updating the numbers is that COHR, CLS and MU remain the three stocks I would begin with, but the full 10-stock ranking contains several opportunities that may be almost as attractive—particularly MRVL and QCOM.


Executive ranking

RankCompanySept. 1 priceAI roleCurrent stanceAlpha score
1Coherent (COHR)$272.03Optical interconnect / photonicsBUY9.6/10
2Celestica (CLS)$296.24 USAI servers / switches / hardware platformsBUY9.5/10
3Micron (MU)$933.44HBM / DRAM / NANDBUY, staged9.3/10
4Marvell (MRVL)$210.40Custom silicon / networkingBUY9.1/10
5Qualcomm (QCOM)$166.61Edge AI + emerging data-center computeBUY8.9/10
6Vertiv (VRT)$255.97Power / coolingBUY on weakness8.6/10
7Broadcom (AVGO)$368.55Custom AI ASICs / networkingBUY after earnings clarity8.5/10
8Credo (CRDO)$206.63High-speed copper/optical connectivityStarter only8.2/10
9Applied Optoelectronics (AAOI)$103.39Optical transceiversSpeculative BUY7.8/10
10Bloom Energy (BE)$213.63Behind-the-meter data-center powerWAIT / starter only7.5/10

Prices are September 1 U.S. closes where available. COHR closed at $272.03, MU at $933.44, MRVL at $210.40, QCOM at $166.61, VRT at $255.97, CRDO at $206.63, AAOI at $103.39 and BE at $213.63. CLS closed around $296.


1. Coherent — COHR

My #1 near-term AI-rotation idea

At $272.03, COHR is roughly 38% below its $440 52-week high. That alone doesn't make something inexpensive, but the underlying business has continued moving in the opposite direction.

Fiscal Q4 revenue reached $2.05 billion, while non-GAAP EPS was $1.74. More importantly, management guided fiscal Q1 2027 revenue to $2.2–$2.4 billion and non-GAAP EPS to $1.85–$2.05.

That means the stock has experienced a major multiple reset while the company's operating trajectory remains positive.

The strategic attraction is optical connectivity. AI clusters require exponentially more bandwidth between accelerators, racks and data centers. As accelerator performance rises, connectivity becomes a limiting factor. That places optical transceivers, lasers, photonics and datacom components directly in the AI capital-spending stream.

My price map

COHRAction
$265–$280Buy first tranche
$245–$260Strong add
$225–$240Aggressive add if fundamentals intact
>$315Stop chasing; reassess

I would expect the first meaningful rerating to take COHR toward approximately $320–$340. A successful FY2027 ramp could eventually justify $375–$425+.

The risk is that optical components remain cyclical. If hyperscaler capex suddenly slows, COHR's multiple can contract rapidly.

12-month working range: $360–$425.


2. Celestica — CLS

Best combination of quality and growth

Celestica may be the strongest business in this group at today's price.

The company has raised 2026 revenue guidance to $20.5 billion and adjusted EPS guidance to $11.30, representing expected year-over-year growth of approximately 65% and 87%, respectively. Management has also said it expects growth to accelerate again in 2027.

At approximately $296, that $11.30 EPS outlook implies a price-to-current-guidance ratio of roughly:

$296 ÷ $11.30 ≈ 26.2×

For a company producing that level of earnings growth, that is considerably more reasonable than the headline stock chart suggests.

CLS's 52-week range is roughly $183.66–$474.02, putting the shares almost 38% below the high.

My price map

CLS — NYSEAction
$285–$305Buy
$265–$280Strong add
$245–$260Exceptional opportunity if outlook unchanged
>$340Don't chase

For Canadians, the TSX listing is particularly useful. The investment thesis is the same; currency simply changes the quoted share price.

12-month working range: $375–$450.

I would not require CLS to revisit its previous $474 high for this investment to work very well.


3. Micron — MU

The most unusual dislocation of the group

This is where our hedge-fund discussion matters.

Micron was indeed one of the enormous positions held by Situational Awareness, the highly leveraged AI-focused fund that suffered a 67% July loss and was pressured to liquidate most of its roughly $16 billion public-equity portfolio. Citadel purchased much of that portfolio and subsequently disposed of more than 80% of its acquired risk. Reuters confirms the forced unwind.

More specifically, the fund's June filings showed Micron and SanDisk accounting for more than 56% of the portfolio. Micron subsequently fell roughly 24% in July.

So this is one situation where we can reasonably say:

At least part of the selloff was related to portfolio mechanics and leverage rather than Micron's operating performance.

Micron's latest reported quarter was extraordinary: revenue of $41.46 billion, non-GAAP EPS of $25.11 and operating cash flow of $25.39 billion.

MU closed September 1 at $933.44, down 2.64% for the day.

My price map

MUAction
$900–$950First tranche
$850–$890Strong add
$800–$840Aggressive add
>$1,025Wait for consolidation

I would not buy a full MU position at once because memory is notoriously cyclical and expectations have risen enormously.

Nevertheless, this may be the stock with the best chance of a violent rebound if investors conclude the July forced-selling episode has completely cleared.

12-month working range: $1,150–$1,350, with materially greater upside possible if HBM pricing remains unusually strong.


A correction to our earlier hedge-fund discussion

After checking the primary/current reporting more carefully, I would refine what I told you earlier.

There is strong evidence for forced selling affecting MU, and there is evidence that Bloom Energy was also a major Situational Awareness holding. The fund's other disclosed major holdings included SanDisk, Taiwan Semiconductor and Nebius.

I do not have equivalent evidence tying COHR or CLS directly to that forced liquidation.

So I would no longer characterize their corrections as proven consequences of the Situational Awareness unwind.

That distinction matters.


4. Marvell — MRVL

The stock that almost breaks into the top three

MRVL is becoming increasingly difficult to ignore.

It reported record fiscal Q2 2027 revenue of $2.739 billion, up 37% year over year, while data-center revenue growth accelerated to 46%. Management said AI-related bookings remain exceptionally strong and expects growth to accelerate through the remainder of fiscal 2027.

Yet the shares suffered a severe post-earnings correction.

MRVL closed at $241.45 on August 27, fell more than 10% on August 28, and finished September 1 at $210.40.

That is exactly the type of earnings-related dislocation I look for.

Entry strategy

$200–$215 is attractive.

Below $195, I would become significantly more aggressive provided no customer-loss information emerges.

MRVL is particularly interesting because it touches both sides of the AI infrastructure equation:

custom accelerators and high-speed connectivity.

12-month working range: $270–$325.

If you asked me which stock could displace MU from the top three, MRVL would be the one.


5. Qualcomm — QCOM

The sleeper

QCOM closed September 1 at only $166.61.

That valuation reflects the market's continuing tendency to treat Qualcomm primarily as a smartphone-chip company.

But Qualcomm is increasingly positioning itself across:

edge AI,
automotive,
robotics,
industrial systems,
PC computing,
and now data-center AI.

Its investor materials explicitly highlight a comprehensive data-center roadmap, while the company continues expanding its AI/high-performance-compute positioning.

This is therefore the stock in the ten where the AI optionality is least fully priced in.

That doesn't make QCOM the stock most likely to surge tomorrow. It makes it one of the best asymmetric opportunities if the market begins assigning value to its data-center effort.

My entry range

$160–$170: Buy.

$150–$158: Strong buy.

Below $150 without a fundamental deterioration would be especially attractive.

12-month working range: $205–$235.

For a multi-year Physical-AI portfolio, I would actually rank QCOM above several stocks that rank higher here on short-term momentum.


6. Vertiv — VRT

The picks-and-shovels power winner

AI accelerators are useless without power conversion, thermal management and cooling.

Vertiv sits almost perfectly in this bottleneck.

Q2 was strong enough for management to raise full-year guidance. It now expects approximately $14 billion in 2026 sales, around 31% organic growth, and adjusted EPS of approximately $6.65–$6.75, roughly 60% above 2025 at the midpoint.

At $255.97, however, that implies roughly:

$255.97 ÷ $6.70 ≈ 38× adjusted 2026 EPS.

That is why VRT ranks #6 rather than #2.

The company is excellent.

The valuation is still demanding.

Shares have nevertheless fallen about 20% over the preceding three months.

Entry range

$240–$255: acceptable starter.

$220–$235: very attractive.

Below $215: strong buy, assuming guidance holds.

12-month working range: $310–$350.


7. Broadcom — AVGO

Possibly the best AI company here—but not necessarily the best entry today

Broadcom's fundamentals are astonishing.

Fiscal Q2 AI semiconductor revenue reached $10.8 billion, increasing 143% year over year, driven by custom AI accelerators and networking.

That is precisely where the AI capex cycle is going.

But AVGO reports September 2, meaning buying aggressively tonight would effectively be making an earnings-event bet. Broadcom closed September 1 around $368.55 and remains well below its $495 52-week high.

I therefore prefer:

wait for tomorrow's earnings reaction.

A good report followed by a sell-the-news decline could give us a much better entry.

12-month working range: $440–$500, subject to tomorrow's numbers.


8. Credo — CRDO

Tremendous growth, dangerous expectations

Credo is one of the purest AI-connectivity companies available publicly.

Its just-reported fiscal Q1 2027 revenue was $479 million, up 114.7% year over year, while non-GAAP net income increased approximately 140%.

Yet CRDO fell 8.65% today, closing at $206.63, after already declining sharply from the $280 area in mid-August.

This is interesting—but different from CLS.

CRDO carries much more valuation risk because the market already recognizes the growth story.

Entry range

$195–$210: starter.

$175–$190: meaningful buy.

Below $170: potentially very attractive.

I would not build the entire position today.

12-month working range: $260–$310.


9. Applied Optoelectronics — AAOI

High-risk optical torque

AAOI is the smallest and most speculative optical-networking idea on this list.

The shares closed September 1 at $103.39, down about 4%, versus a 52-week range of roughly $18.50–$233.67.

That enormous range tells you almost everything you need to know about the risk.

If AI optical transceiver demand remains strong and AAOI executes manufacturing expansion correctly, the upside can be enormous.

But this is not COHR.

The balance sheet, customer concentration, margins and execution risk justify a substantially smaller position.

Entry range

$95–$105: speculative starter.

$80–$90: attractive speculation.

I would limit AAOI to perhaps 3–5% of an AI infrastructure basket.

12-month working range: $140–$180, but with unusually wide error bars.


10. Bloom Energy — BE

Fantastic theme; difficult stock price

Bloom's underlying growth is extraordinary.

Q2 revenue reached $1.065 billion, increasing 166% year over year, and management raised full-year revenue guidance to $3.9–$4.2 billion, approximately 100% growth at the midpoint.

And there is a forced-selling angle here too: Bloom was among Situational Awareness's significant holdings and dropped roughly 31% during the July AI unwind.

BE subsequently recovered and closed September 1 at $213.63.

So why only #10?

Because the valuation now assumes a tremendous amount of future success.

The business opportunity may be one of the largest in the entire portfolio, but price discipline is essential.

Entry range

$180–$195: interesting.

$160–$175: buy.

Below $155: strong speculative buy.

At $213+, I would wait.


The portfolio I am planning to construct

If the objective is maximum reasonable alpha rather than simply owning all ten equally, I would not use a 10%/10%/10% structure.

For a hypothetical CAD $100,000 AI-infrastructure portfolio, mine would look approximately like this:

CompanyWeightCAD amountRole
COHR17%$17,000Optical connectivity
CLS17%$17,000AI hardware infrastructure
MU14%$14,000Memory/HBM
MRVL12%$12,000ASIC/network silicon
QCOM11%$11,000AI optionality / Physical AI
VRT9%$9,000Power/cooling
AVGO8%$8,000Custom compute/networking
CRDO5%$5,000High-speed connectivity
AAOI3%$3,000High-beta optical
BE4%$4,000Distributed power

That puts 71% of the portfolio in my top five.

I prefer that concentration because the purpose of this portfolio isn't index-like diversification. It is targeted participation in the physical infrastructure bottlenecks created by AI.


But I would not invest the $100,000 today

This is perhaps the most important part of the report.

With Treasury yields rising, equities weak on September 1, and September historically prone to volatility, I would deploy approximately:

Stage 1 — Now: 40%

Establish COHR, CLS, MU, MRVL and QCOM.

Small VRT/CRDO positions are a maybe.

Stage 2 — Another 5–8% sector correction: 30%

Add primarily to whichever of COHR / CLS / MRVL / QCOM falls without a corresponding earnings deterioration.

Stage 3 — Capitulation or catalyst confirmation: 30%

Use this after either:

a genuine September washout,

or evidence that the AI-infrastructure group has established a higher low and resumed leadership.

This avoids the two mistakes investors commonly make during a correction:

waiting forever for the absolute bottom, or

spending all available cash during the first decline.


The three I am looking to buy by next week

If you wanted to keep this exceptionally simple and buy only three, 

🥇 COHR

Best rebound setup

$272 is already deep in my preferred first-entry zone.

Its business is growing while its stock has fallen roughly 38% from the high. The connectivity bottleneck is real, and management's FY2027 opening-quarter guidance remains strong.

🥈 CLS

Best business-quality setup

At approximately 26× management's $11.30 EPS guidance, with projected EPS growth approaching 90%, I think the risk/reward is exceptional if Celestica executes.

🥉 MU

Best forced-liquidation/recovery setup

The hedge-fund liquidation is real—not merely speculation—and MU's financial performance is dramatically stronger than its July price action suggested.


Investing a moderate $25,000 as an example

Given today's prices, and although MRVL has become much more attractive after its post-earnings drop.

I like this allocation as entry positions:

PositionUltimate allocationInitial purchase now
COHR$10,000$5,000
CLS$8,750$4,500
MU$6,250$2,500
Cash held back—$13,000

So I would put about $12,000 to work now and retain roughly $13,000.

If September gives us another 7–10% AI-infrastructure flush, that cash becomes extremely valuable.

And if the market simply turns higher?

A retail investor would already own meaningful starter positions.


Which one is most likely to “pop” first?

My ranking over the next 30–90 days is slightly different from my long-term ranking:

RankStockWhy
1MUForced-selling overhang + enormous HBM earnings + potential technical snapback
2COHRLarge drawdown + optical-networking rerating
3MRVLFresh post-earnings dislocation
4CLSFundamentals increasingly difficult for market to ignore (Canadian gem)
5CRDOHighest beta if connectivity trade resumes

Over 12–24 months, however, I would put CLS and COHR ahead of MU because their growth is less dependent on memory-cycle economics.


What could invalidate this entire thesis?

There are five things that would negatively impact this scenario!

  1. Hyperscaler capex cuts. If Microsoft, Meta, Amazon, Google, Oracle or xAI start materially reducing AI infrastructure budgets, almost everything in this portfolio gets hit. (moderate risk)
  2. Long-duration rates. Today's bond-market selloff matters. Higher yields compress the multiples investors will pay for fast-growth technology. (watch this)
  3. Networking oversupply. A sudden inventory build would hit COHR, CRDO and AAOI disproportionately.(Minimal risk)
  4. Memory pricing reversal. MU's earnings are spectacular precisely because memory economics have become spectacular. That cuts both ways.(Moderate)
  5. AI architecture becoming materially less infrastructure-intensive. This is the existential risk to the entire “trillions of dollars of physical AI infrastructure” thesis.(Moderate risk)

None of those is my base case today.


My September hierarchy

Starter positions by next week

COHR — CLS — MU — MRVL — QCOM

Buy on weakness

Riskier at present

CRDO — AAOI

Wait for a better price

BE

And the most important conclusion from this exercise is that we do not need NVIDIA to keep winning at the same rate for this portfolio to work.

In fact, its strongest scenario may be one in which AI spending keeps climbing but the economic value begins migrating away from the GPU itself toward...

memory, optics, networking, custom silicon, electrical infrastructure and cooling.

COHR, CLS, MU and MRVL now give us four particularly compelling ways to own it at materially reset prices.

I am treating $265–280 COHR, $285–305 CLS and $900–950 MU as actionable first-entry zones right now, while keeping roughly half the intended capital available for September volatility.


Thursday, December 18, 2025

My small-investor–oriented framework for targeting investments going into 2026

Caution: If you are a young person, starting out in your career, or if you are in Mid-Career and concerned about the future of employment, I bring to your attention this note from InvestorsPlace Guru, Luke Lango: 

"if you have zero exposure to the companies building the infrastructure of the future, you are betting your entire financial existence on your ability to outwork software that doubles in ability every 18 months.

That is a terrible bet.

The only true hedge against the devaluation of your labor is to own stock in the companies that are benefiting from labor devaluation. You need to be on the receiving end of that wealth transfer".

Now, Forward: 
Grounded in the dominant structural forces already in motion (AI infrastructure, re-industrialization, energy security, biotech inflection points, and geopolitical supply-chain realignment). This is written from the perspective of capital discipline, asymmetric upside, and survivability through volatility.

1. AI Infrastructure & “Picks-and-Shovels”

AI is no longer a software story alone. The bottlenecks are power, cooling, compute density, memory, and networking. These constraints intensify through 2026.

What to target

  • Data-center infrastructure: power management, liquid cooling, thermal systems

  • Semiconductors beyond GPUs: memory (HBM), interconnects, analog/power chips

  • AI-optimized hardware platforms rather than consumer AI apps

Small-investor edge

  • These companies earn revenue regardless of which AI model “wins.”

  • Long contract cycles = visibility.

  • Less valuation risk than pure AI software.

Risk profile: Medium
Reward profile: High but steadier than AI software


2. Energy, Grid Modernization & Energy Storage

AI turns electricity into a strategic asset. Data centers, EVs, reshoring, and defense manufacturing are colliding with aging grids.

What to target

  • Grid infrastructure (transformers, substations, power electronics)

  • Energy storage (lithium, sodium-ion, grid-scale batteries)

  • Nuclear (SMRs) as baseload complements to renewables

Small-investor edge

  • Many grid suppliers are under-owned and not “AI-branded.”

  • Governments are forced buyers.

Risk profile: Low–Medium
Reward profile: Medium–High with strong downside protection


3. Critical Minerals & Strategic Materials

This is industrial policy investing, not commodity speculation. Rare earths, lithium, graphite, nickel, and copper are strategic chokepoints.

What to target

  • Non-Chinese supply chains (U.S., Canada, Australia)

  • Processing & separation, not just mining

  • Assets tied to defense, EVs, robotics, and grid storage

Small-investor edge

  • Valuations are still depressed.

  • Government funding, offtake agreements, and M&A are catalysts.

Risk profile: High
Reward profile: Very high (binary upside)


4. Biotech at Inflection (CRISPR, Base Editing, RNA)

After a brutal bear market, science has outpaced valuations. 2025–2026 is heavy with Phase-2/3 data and potential acquisitions.

What to target

  • Platform technologies, not single-asset stories

  • Companies with cash runway into 2027

  • Assets attractive to big pharma

Small-investor edge

  • Retail often exits at peak pessimism.

  • Takeovers re-price stocks overnight.

Risk profile: High
Reward profile: Very high (event-driven)


5. Quantum Computing (Selective Exposure)

Quantum is moving from science projects to government and enterprise pilots. 2026 is about validation, not mass adoption.

What to target

  • Companies with real deployments and revenue

  • Hardware + software + services ecosystems

  • Government and hyperscaler partnerships

Small-investor edge

  • Early exposure before institutional mandates kick in.

  • Volatility favors disciplined accumulation.

Risk profile: Very High
Reward profile: Extreme asymmetric upside


6. Defense, Autonomy & “Physical AI”

Defense spending is structurally rising, not cyclical. AI + autonomy is redefining warfare and logistics.

What to target

  • Sensors, autonomy software, robotics

  • Suppliers rather than prime contractors

  • Dual-use (civil + defense) technologies

Small-investor edge

  • Less political headline risk than primes.

  • Faster growth rates.

Risk profile: Medium
Reward profile: High


7. Gold, Real Assets & Inflation Hedges (Selective)

Persistent fiscal deficits, geopolitical risk, and currency debasement argue for insurance exposure, not speculation.

What to target

  • High-quality gold producers

  • Royalty/streaming models

  • Avoid over-leveraged miners

Risk profile: Low
Reward profile: Moderate but stabilizing


How a Small Investor Might Allocate (Conceptual)

BucketApprox. WeightPurpose
AI Infrastructure & Semis20–25%Growth with visibility
Energy & Grid15–20%Stability + policy tailwinds
Critical Minerals10–15%Asymmetric upside
Biotech (Inflection)10–15%Event-driven returns
Quantum & Frontier Tech5–10%Moonshot exposure
Defense & Robotics10–15%Structural spending
Gold / Cash Buffer5–10%Volatility control

Key Discipline for 2026

  • Avoid over-concentration in hype narratives

  • Favor infrastructure over apps

  • Insist on balance-sheet survivability

  • Expect volatility — use it

  • Below you’ll find specific Canadian- and U.S.-listed names aligned to the earlier thematic framework, rankings by risk-adjusted return, and model portfolio allocations for three capital levels: $25,000, $50,000, and $100,000. Where possible I’ve prioritized companies with visible revenue, strategic positioning, and multi-year catalysts rather than purely speculative explorers.


1) Thematic Company Lists (Canadian + U.S.)

A. AI Infrastructure & Semiconductors

Canadian-Listed

  • Celestica Inc. (CLS) – electronics manufacturing with strong data-center/Ai infrastructure demand. Investors

U.S./Global

  • NVIDIA (NVDA) – dominant AI accelerator hardware.

  • Broadcom (AVGO) – networking, interconnect, silicon.

  • Advanced Micro Devices (AMD) – AI accelerators, CPUs.

  • Marvell Technology (MRVL) – networking silicon.

Risk Profile: Medium-High
Return Potential: High (leveraged to AI buildouts)


B. Energy & Grid Modernization / Energy Storage

Canadian-Listed

  • Algonquin Power & Utilities (AQN) – regulated power & grid operations across North America. Wikipedia

  • Canadian Solar (CSIQ) – solar + battery storage developer. Wikipedia

U.S.

  • NextEra Energy (NEE) – clean energy + grid scale assets.

  • Enphase Energy (ENPH) – solar microinverters + storage management.

  • Tesla (TSLA) – energy storage + EVs (grid demand proxy).

Risk Profile: Medium
Return Potential: Moderate-High


C. Critical Minerals (Lithium, Copper, Rare Earths, Nickel, Uranium)

Canadian

  • First Quantum Minerals (FM) – copper mining with global footprint. Wikipedia

  • Teck Resources (TECK) – diversified base metals (copper, zinc). Wikipedia

  • Alamos Gold (AGI) – gold producer (inflation/insurance asset). Wikipedia

  • (Optional more speculative) TSXV/CSE juniors: cobalt, rare earths, graphite explorers (subject to due diligence) AInvest

U.S.

  • Albemarle (ALB) – lithium producer. Nai500

  • USA Rare Earth (USAR) – rare earth supply exposure (speculative). Nai500

  • Cameco (CCJ) – uranium producer (strategic energy metal). Investors

Risk Profile: Medium-High to High
Return Potential: High (cyclical + secular tailwinds)


D. Biotech at Inflection

U.S. (Selected Platform/Biotech)

  • 10x Genomics (TXG) – genomic platforms.

  • Beam Therapeutics (BEAM) – base editing tech.

  • CRISPR Therapeutics (CRSP) – gene editing.

  • Moderna (MRNA) – RNA platforms.

Risk Profile: High
Return Potential: Very High (event catalysts)


E. Quantum / Frontier Tech

Canadian

U.S.

  • IonQ (IONQ) – quantum computing (U.S.-listed).

  • Rigetti Computing (RGTI) – quantum hardware.

Risk Profile: Very High
Return Potential: Extreme Asymmetric


F. Defense & Autonomy

Canadian

  • CAE Inc. (CAE.TO) – aerospace & defense systems. KoalaGains

  • Kraken Robotics (PNG.TO) – defense robotics & sensors. KoalaGains

U.S.

  • Lockheed Martin (LMT)

  • Raytheon / RTX (RTX)

  • Northrop Grumman (NOC)

Risk Profile: Medium
Return Potential: Medium-High


G. Gold / Inflation Hedge

Canadian

  • Alamos Gold (AGI) – physical gold producer. Wikipedia

U.S.

  • Newmont Corporation (NEM)

  • Barrick Gold (GOLD)

Risk Profile: Lower
Return Potential: Medium (insurance hedge)


2) Risk-Adjusted Ranking (Highest to Lower)

RankThemeTypical VolatilityExpected Risk-Adjusted Return
1AI Infrastructure & SemiconductorsMedium-HighHigh
2Energy & Grid ModernizationMediumMedium-High
3Critical MineralsHighHigh (cyclical support)
4Defense & AutonomyMediumMedium-High
5Biotech at InflectionVery HighVery High (event risk)
6Quantum / Frontier TechVery HighExtreme (long horizon)
7Gold / Inflation HedgeLowerStable / Moderating

Interpretation:

  • Best blend of growth and volatility control: AI infrastructure and energy grid.

  • Higher expected return but more swings: critical minerals and defense.

  • Highest upside but binary events: biotech and quantum.


3) Model Portfolios

Below are diversified allocations with discrete weightings calibrated for small investors. Each portfolio mixes growth, strategic infrastructure, and risk buffers.


A) $25,000 Portfolio (Balanced Growth)

ThemeAvg %Example Tickers$ Allocation
AI Infrastructure22%NVDA, CLS$5,500
Energy / Grid18%NEE, AQN$4,500
Critical Minerals18%ALB, FM$4,500
Defense12%RTX, CAE$3,000
Biotech10%TXG$2,500
Gold Hedge10%AGI$2,500
Quantum10%IONQ$2,500

B) $50,000 Portfolio (Growth + Stability)

ThemeAvg %Example Tickers$ Allocation
AI Infrastructure24%NVDA, AMD, CLS$12,000
Energy / Grid18%NEE, CSIQ, AQN$9,000
Critical Minerals18%ALB, CCJ, TECK$9,000
Defense12%LMT, CAE$6,000
Biotech12%TXG, BEAM$6,000
Gold Hedge6%NEM$3,000
Quantum10%IONQ, QSE$5,000

C) $100,000 Portfolio (Higher Conviction + Diversified)

ThemeAvg %Example Tickers$ Allocation
AI Infrastructure26%NVDA, AVGO, CLS$26,000
Energy / Grid18%NEE, AQN, ENPH$18,000
Critical Minerals20%ALB, FM, TECK, CCJ$20,000
Defense12%LMT, RTX, CAE$12,000
Biotech12%TXG, BEAM, CRSP$12,000
Gold Hedge4%AGI, NEM$4,000
Quantum8%IONQ, RGTI$8,000

4) Practical Notes & Risk Controls

Rebalancing:

  • Quarterly rebalance with cutoffs for stop-loss discipline.

  • Reduce biotech/quantum if catalysts slip.

Diversification guardrails:

  • No single ticker >10% (except AI infrastructure leaders).

  • Tactical cash buffer (5–10%) during drawdowns.

Tax considerations: